Medscape has put together a background piece on orforglipron, the oral GLP-1 from Eli Lilly that is sold as Foundayo.
Recap by typeshit. Full story at Medscape.
The study of over 87,000 matched patients 65 and up also found 28% fewer liver decompensation events, but no drop in heart attack or stroke and more osteoporosis diagnoses.
18:05
Dr. Stirrett walks through three pointers for people on tirzepatide, framed as part of a broader GLP-1 guide. His advice, not a set protocol.
He walks through an Azoury et al study in the October 2026 Plastic and Reconstructive Surgery that uses global health network data to compare the two weight loss routes.
The claim credits GLP-1 drugs' effects on insulin sensitivity and inflammation for changes in dermatologic conditions. No study is cited.
A survey presented at the EADV 2026 Congress found more nail lifting and color changes in GLP-1 users, but the link weakened after adjustments.
A post on the trial pitting Lilly's tirzepatide against dulaglutide for cardiovascular outcomes in people with type 2 diabetes.
Loading…